I N Colmers1, S L Bowker, L A Tjosvold, J A Johnson. 1. Department of Public Health Sciences, University of Alberta, 2-040 Li Ka Shing Center Edmonton, Alberta, T6G 2E1 Canada.
Abstract
AIMS: To determine whether data from observational studies supports the hypothesis of an increased risk of overall and site-specific cancer among individuals with diabetes using exogenous insulin therapies. METHODS: We conducted a comprehensive search of nine key biomedical databases for all years up to December 2011, restricted to the English language. Data from cohort and nested case-control studies were included in random effects meta-analyses of site-specific and overall cancer incidence comparing ever use and new use of: (1) insulin to no insulin and; (2) insulin glargine to other insulins. RESULTS: The search yielded 3052 unique citations, of which 19 were selected for inclusion, representing data for 1,332,120 people and 41,947 cancers. Pancreatic cancer risk was increased among new users of insulin (RR: 3.18, 95%CI: 3.27-3.71, I(2)=32%). New use of insulin glargine was associated with an increased risk of pancreatic cancer (RR: 1.63, 95%CI: 1.05-2.51, I(2)=0%) and prostate cancers (RR: 2.68, 95%CI: 1.50-4.79, I(2)=0%) but a decreased risk of colorectal cancer (RR: 0.78, 95%CI: 0.64-0.94, I(2)=15%). CONCLUSION: New use of insulin or insulin glargine was associated with an increased risk of pancreatic cancer, possibly due to reverse causality. New use of insulin glargine was associated with a decreased risk of colorectal cancer but an increased risk of prostate cancer. Our results should be interpreted with caution due to limitations of included studies.
AIMS: To determine whether data from observational studies supports the hypothesis of an increased risk of overall and site-specific cancer among individuals with diabetes using exogenous insulin therapies. METHODS: We conducted a comprehensive search of nine key biomedical databases for all years up to December 2011, restricted to the English language. Data from cohort and nested case-control studies were included in random effects meta-analyses of site-specific and overall cancer incidence comparing ever use and new use of: (1) insulin to no insulin and; (2) insulinglargine to other insulins. RESULTS: The search yielded 3052 unique citations, of which 19 were selected for inclusion, representing data for 1,332,120 people and 41,947 cancers. Pancreatic cancer risk was increased among new users of insulin (RR: 3.18, 95%CI: 3.27-3.71, I(2)=32%). New use of insulinglargine was associated with an increased risk of pancreatic cancer (RR: 1.63, 95%CI: 1.05-2.51, I(2)=0%) and prostate cancers (RR: 2.68, 95%CI: 1.50-4.79, I(2)=0%) but a decreased risk of colorectal cancer (RR: 0.78, 95%CI: 0.64-0.94, I(2)=15%). CONCLUSION: New use of insulin or insulinglargine was associated with an increased risk of pancreatic cancer, possibly due to reverse causality. New use of insulinglargine was associated with a decreased risk of colorectal cancer but an increased risk of prostate cancer. Our results should be interpreted with caution due to limitations of included studies.
Authors: Maureen Sanderson; Loren Lipworth; Martha J Shrubsole; Shaneda Warren Andersen; Xiao-Ou Shu; Wei Zheng; Margaret K Hargreaves; William J Blot Journal: Cancer Causes Control Date: 2019-04-02 Impact factor: 2.506
Authors: Ashwini Arvind; Zoe N Memel; Lisa L Philpotts; Hui Zheng; Kathleen E Corey; Tracey G Simon Journal: Metabolism Date: 2021-04-21 Impact factor: 13.934
Authors: Przemyslaw Rys; Piotr Wojciechowski; Agnieszka Rogoz-Sitek; Grzegorz Niesyczyński; Joanna Lis; Albert Syta; Maciej T Malecki Journal: Acta Diabetol Date: 2015-01-14 Impact factor: 4.280
Authors: Heleen K Bronsveld; Bas ter Braak; Øystein Karlstad; Peter Vestergaard; Jakob Starup-Linde; Marloes T Bazelier; Marie L De Bruin; Anthonius de Boer; Christine L E Siezen; Bob van de Water; Jan Willem van der Laan; Marjanka K Schmidt Journal: Breast Cancer Res Date: 2015-08-05 Impact factor: 6.466